Navigation Links
ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
Date:6/17/2008

d supply of clinical material until transfer of manufacturing.

TB-403 (Anti-PIGF) has completed an initial Phase I clinical trial and recently received approval to enter a Phase Ib dose escalation trial. This Phase Ib trial will be conducted in patients with advanced cancer and is due to commence shortly in Denmark.

TB-403 has the potential to be a major advance in the treatment of cancer. It is a humanized monoclonal antibody that blocks the formation of the new blood vessels that are needed by solid tumours to support their growth. TB-403 has the potential to minimize both the growth and spread of cancer cells.

Professor Désiré Collen, CEO and Chairman of ThromboGenics, said: "TB-403 has generated a great deal of interest from the pharmaceutical community. Therefore, we are delighted that we have signed this major licensing agreement with Roche, given their expertise and success in bringing novel anti-cancer agents to the market. This deal represents a significant milestone in ThromboGenics' development as a company. It also reflects TB-403's potential as a promising treatment for cancer, and is a testament to the hard work and high quality science on which ThromboGenics' business is based. The funding from this deal also gives us the financial resources to continue to build our strong pipeline. We look forward to working with Roche, and to the successful development of this unique anti-cancer agent."

Svein Mathisen, CEO of BioInvent, commented on the deal: "We believe that TB-403 has great potential for the treatment of cancer, with its unique mode of action targeting PlGF, and are delighted that Roche has recognised this potential. This agreement demonstrates our ability to identify innovative projects and to realize the clinical potential of a therapeutic antibody. We look forward to seeing the product progress further through clinical development and towards market."

Dan Zabrowski, Global Head of Pharma Partnering, Roche adde
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. ThromboGenics N.V. - Business Update
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Fertility Associates of Memphis has announced a new ... network of more than 20 contributing fertility practices ... access to a national pool of frozen donor ... of Memphis is the only fertility clinic in the ... Dr. William Kutteh , director of Fertility Associates of ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one of the ... Maroulis, Pharm.D. to the newly created position of Vice ... position, Dr. Maroulis will continue to manage the entire ... multi-site pharmacies as the company expands. Dr. Maroulis has ... he has served in many different capacities in the ...
(Date:12/19/2014)... , Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... today that they have been acquired by Roche (SIX: ... a privately held company that provides a big data ... sequencing (NGS) data for the academic and translational research ... Unit, and will continue to focus on development of ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy ... has an expanded team of Regional Pharmaceutical Care ... prescriber offices in their regions, with specific areas ... a variety of Regional Pharmaceutical Care Liaisons specializing ... hepatitis C help prescribers understand all the new ...
Breaking Biology Technology:Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3
... 11 Pressure,BioSciences, Inc. (Nasdaq: PBIO ... it has entered into a Cooperative Research ... Army Medical Research Institute of,Infectious Diseases (USAMRIID). ... use of the Company,s patented pressure cycling ...
... and safety of food supply, as well as increasing concerns ... to experience spiraling growth given the recent success of commercialized ... pipeline. , ... San Jose, California ...
... Update on Key Regulatory Milestones, SEATTLE, Sept. 11 ... MTA: CTIC) announced today that it will host an,investor ... investor day will,provide an update from executive management on ... meeting will be an,invitation-only event. A webcast and live ...
Cached Biology Technology:Pressure BioSciences, Inc. Announces Research Agreement With the US Army Medical Research Institute of Infectious Diseases (USAMRIID) 2Pressure BioSciences, Inc. Announces Research Agreement With the US Army Medical Research Institute of Infectious Diseases (USAMRIID) 3Pressure BioSciences, Inc. Announces Research Agreement With the US Army Medical Research Institute of Infectious Diseases (USAMRIID) 4Pressure BioSciences, Inc. Announces Research Agreement With the US Army Medical Research Institute of Infectious Diseases (USAMRIID) 5Long-Term Investments Remain Critical to Biotechnology Industry Growth, According to a New Report by Global Industry Analysts 2Long-Term Investments Remain Critical to Biotechnology Industry Growth, According to a New Report by Global Industry Analysts 3Long-Term Investments Remain Critical to Biotechnology Industry Growth, According to a New Report by Global Industry Analysts 4
(Date:12/11/2014)... N.C. , Dec. 10, 2014  That blood pressure ... quite a while. Hypertension – the medical term for high ... the early 1800s, and the inflatable cuff that,s used in ... doesn,t, however, mean there,s nothing new about hypertension, its triggers ... long-held beliefs about the condition and the best ways to ...
(Date:12/10/2014)... -- You,ve been here before: you desperately need to sign ... site key or the answer to your secret question. What,s ... Today, Hoyos Labs , a digital infrastructure ... put an end to the frustration that comes with usernames, ... leverages a user,s smartphone to acquire his or her biometrics ...
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical Center ... for its School of Medicine. Funding for this $50 ... campaign that will be publicly launched next summer. ... in the former 60 series R.J. Reynolds Tobacco Company ... Construction will begin immediately with plans to be ready ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... honeybee hives arrests the growth of prostate cancer cells and ... at the University of Chicago Medicine. Caffeic acid phenethyl ... propolis, the resin used by bees to patch up holes ... natural remedy for conditions ranging from sore throats and allergies ...
... Biology Reports published today argues that recent advances ... of the global demand for liquid transportation fuels, drastically reducing ... burning fossil fuels, without having an impact on food production. ... of detrimental climate change is the emission of greenhouse gasses ...
... brain activity in the rat brain that play a ... decision-making. The discovery, which builds on the team,s previous ... post-traumatic stress syndrome. The researchers previously identified patterns ... region critical for memory storage. The patterns sometimes represented ...
Cached Biology News:Beehive extract shows potential as prostate cancer treatment 2Beehive extract shows potential as prostate cancer treatment 3Better plants for biofuels 2Rats recall past to make daily decisions 2Rats recall past to make daily decisions 3
... convenient, and efficient native protein concentration following ... spin column to make handling easy. The ... which were electro-eluted in their native condition. ... high binding capacity fo all pH values. ...
... optically clear polystyrene with frosted labeling ... for cell counting. 100% integrity tested. ... new product number, created to easily ... no availability yet, please order under ...
... The Corning CellBIND surface is produced ... a more hydrophilic surface giving more consistent, ... yields. CellBIND enhances cell attachment and growth ... serum-free medium. • CellBIND may provide a ...
... system, 100-240 V, uses xMAP technology for ... proteins and peptides in one microplate well. ... to 100 color-coded bead sets, each of ... reactant (enzyme substrates, receptors, antigens, or antibodies) ...
Biology Products: